BioSpace News Archive

Eliem Therapeutics, Inc. (NASDAQ: ELYM), today announced the closing of its initial public offering of 7,360,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 960,000 additional shares of common stock, at a public offering price of $12.50 per share

Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction -based DNA manufacturing and nucleic acid-based technologies, announced consolidated financial results for the three and nine months ended June 30, 2021.

Viveve Medical, Inc., a medical technology company focused on women’s intimate health, reported financial results for the quarter ended June 30, 2021, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today.

Dyadic International, Inc., a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics announced its financial results for the second quarter of 2021 and highlighted recent Company progress.

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three and six months ended June 30, 2021 and provided a business update.

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2021 and provided a business update.

CytRx Corporation, a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, commented on its results for the second quarter ended June 30, 2021.

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced financial results for the three-month period ended June 30, 2021 and provided a corporate update.

Humanigen, Inc., a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm’” with its lead drug candidate, lenzilumab, provided a corporate and regulatory update and reported financial results for the second quarter and six months ended June 30, 2021.

ENDRA Life Sciences Inc., a pioneer of Thermo Acoustic Enhanced UltraSound, reported financial results for the three months ended June 30, 2021 and provided a business update.